Cross-talk between probiotic lactobacilli and host immune system

Kemgang, Tanedjeu Sonfack; Kapila, Suman; Shanmugam, Venkatesa Perumal; Kapila, Rajeev

doi:10.1111/jam.12521

Cited by 94 publications

(62 citation statements)

References 126 publications

(228 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, there is a vast research about the role of specific food components in enhancing immune responses against a challenge with the aim to improve health and reduce disease risks [3]. In this line, the interest in probiotics has substantially increased over the last two decades, which are well-defined as ‘live bacteria that offer a health benefit to the host when administered in adequate amounts’ [4].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Lactobacillus coryniformis CECT5711 strain as a coadjuvant in a vaccination process: a randomised clinical trial in healthy adults

et al. 2017

View full text Add to dashboard Cite

BackgroundAlthough the effects of probiotics on the immune system have been extensively evaluated under disease states, their role in healthy situations remains unclear, since changes are hardly expected under immunological homeostasis. EFSA indicates that vaccination protocols could be used to evaluate the potential role of probiotics to improve the immune response against antigen challenges. The aim of the study was to evaluate the effect of Lactobacillus coryniformis CECT5711 (Lc) on the specific immunity of healthy volunteers undergoing vaccination with Hepatitis A virus (HAV).MethodsOne hundred twenty-three healthy adults were randomised into three groups to follow a 6-week (wk) intervention and all received an intramuscular HAV vaccine 2 weeks after starting the intervention: 1) PRO1 received Lc for 2weeks (1 capsule/day; 3 × 109 CFU/capsule) and placebo capsules after vaccination; 2) PRO2 received a daily capsule of Lc (3 × 109 cfu/day) before and after the challenge; 3) Control group (C) received a daily placebo capsule before and after the vaccine. Blood samples were collected at the beginning (visit 1; V1) and after 2 (V2) and 6 weeks (V3) of the intervention. At each visit, lymphocyte subset counts and cytokine levels were analysed. Specific HAV antibodies were analysed at V1 and V3. To evaluate differences between groups, one-way ANOVA with Bonferroni post-hoc test were used regarding lymphocyte subset counts and specific HAV antibodies production, and Friedman test of related samples and Kendall concordance coefficient for cytokines production. Chi square test was used to analyse seroconversion rates.ResultsSpecific HAV antibodies were significantly higher in PRO1 (50.54 ± 29.57) compared to C (36.23 ± 16.45) (P = 0.017) and showed an intermediate value in PRO2 (41.61 ± 15.74). Seroconversion rates were similar in the three groups (97.3, 92.3 and 97.4% in C, PRO1 and PRO2 respectively). Memory T-helper lymphocytes increased in V3 vs. V1 (P = 0.032) in PRO2. No differences were found in cytokine concentrations.ConclusionMixed results have been found regarding the usefulness of Lc supplementation to increase the antigen-specific antibody response to an immune challenge. Clinical trial registration number: EudraCT Number 2016-000183-42. Registered 19 January 2016. Retrospectively registered.Electronic supplementary materialThe online version of this article (doi:10.1186/s12986-016-0154-2) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of Lactobacillus coryniformis CECT5711 strain as a coadjuvant in a vaccination process: a randomised clinical trial in healthy adults

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Furthermore, it was shown that defensins could suppress early events in inflammation and enhance systemic antibody responses 18 . Since several reports have indicated that lactobacilli enhance the production of antimicrobial peptides in mucosal surfaces such as the gut 19 , we examined whether mBD14 could be induced in distant mucosal surfaces (such as gingival tissues) of mice gastrically intubated with LG2055. One week after the onset of gastric intubation with LG2055, significant expression of mBD14-specific mRNA was detected in the small intestine, gingival tissue, and tongue (Fig.…”

Section: Resultsmentioning

confidence: 99%

Oral administration of Lactobacillus gasseri SBT2055 is effective in preventing Porphyromonas gingivalis-accelerated periodontal disease

Kobayashi

Sakai

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Probiotics have been used to treat gastrointestinal disorders. However, the effect of orally intubated probiotics on oral disease remains unclear. We assessed the potential of oral administration of Lactobacillus gasseri SBT2055 (LG2055) for Porphyromonas gingivalis infection. LG2055 treatment significantly reduced alveolar bone loss, detachment and disorganization of the periodontal ligament, and bacterial colonization by subsequent P. gingivalis challenge. Furthermore, the expression and secretion of TNF-α and IL-6 in gingival tissue was significantly decreased in LG2055-administered mice after bacterial infection. Conversely, mouse β-defensin-14 (mBD-14) mRNA and its peptide products were significantly increased in distant mucosal components as well as the intestinal tract to which LG2055 was introduced. Moreover, IL-1β and TNF-α production from THP-1 monocytes stimulated with P. gingivalis antigen was significantly reduced by the addition of human β-defensin-3. These results suggest that gastrically administered LG2055 can enhance immunoregulation followed by periodontitis prevention in oral mucosa via the gut immune system; i.e., the possibility of homing in innate immunity.

show abstract

“…Previous work has demonstrated that PBio therapy exerts its immunomodulatory effect by regulating signaling through pattern recognition receptors (PRR), including Toll-like receptors (TLRs) (14, 46, 47). In order to better understand the mechanism by which PBio therapy elicits the observed immune changes we describe here, we utilized HEK-293 T cells that had been stably transfected with individual TLRs and a colorimetric reporter gene.…”

Section: Resultsmentioning

confidence: 99%

Enhancement of Microbiota in Healthy Macaques Results in Beneficial Modulation of Mucosal and Systemic Immune Function

Manuzak

Hensley-McBain

Zevin

et al. 2016

The Journal of Immunology

View full text Add to dashboard Cite

Given the critical role of mucosal surfaces in susceptibility to infection, it is imperative that effective mucosal responses are induced when developing efficacious vaccines and prevention strategies for infection. Modulating the microbiota in the gastrointestinal (GI) tract through the use of probiotics (PBio) is a safe and well-tolerated approach to enhance mucosal and overall health. We assessed the longitudinal impact of daily treatment with the VSL#3 probiotic on cellular and humoral immunity and inflammation in healthy macaques. PBio therapy resulted in significantly increased frequencies of B cells expressing IgA in the colon and lymph node (LN), likely due to significantly increased LN T follicular helper cell (Tfh) frequencies and LN follicles. Increased frequencies of IL-23+ antigen presenting cells (APCs) in the colon were found post-PBio treatment, which correlated with LN Tfh. Finally, VSL#3 significantly down-modulated the response of TLR2, TLR3, TLR4 and TLR9-expressing HEK293 cells to stimulation with Pam3CSK4, Poly(I:C), LPS and ODN2006, respectively. These data provide a mechanism for the beneficial impact of PBio on mucosal health and implicates the use of PBio therapy in the context of vaccination or preventative approaches to enhance protection from mucosal infection by improving immune defenses at the mucosal portal of entry.

show abstract

Cross-talk between probiotic lactobacilli and host immune system

Cited by 94 publications

References 126 publications

Evaluation of Lactobacillus coryniformis CECT5711 strain as a coadjuvant in a vaccination process: a randomised clinical trial in healthy adults

Evaluation of Lactobacillus coryniformis CECT5711 strain as a coadjuvant in a vaccination process: a randomised clinical trial in healthy adults

Oral administration of Lactobacillus gasseri SBT2055 is effective in preventing Porphyromonas gingivalis-accelerated periodontal disease

Enhancement of Microbiota in Healthy Macaques Results in Beneficial Modulation of Mucosal and Systemic Immune Function

Contact Info

Product

Resources

About